ABSTRACT
Studied concentration of lactate and pyruvate in patiens with lung tuberculosis with disorders of tolerance to glucosis and glukemic disorders on an empty stomach and in patiens, wich had not such disorders. In patiens with preclinical disorders glicemia discovered increasing to concentrations of lactate and pyruvate in blood. This is indicative of more deep breaches of quality to oxidation the glucose in energetic aerobic reaction, in particular, in tricarboxylic acids cycle. Effect this is a deterioration energy status of the cells. Excess of the formation lactate and pyruvate on background of the effect anty-insulin hormone prevalence and relative insufficiency of the insulin realizes the independent contribution to development hyperglicemia disorders.
Subject(s)
Carbohydrate Metabolism , Hyperglycemia/metabolism , Lactic Acid/blood , Pyruvic Acid/blood , Tuberculosis, Pulmonary/metabolism , Blood Glucose/analysis , Case-Control Studies , Glucose Tolerance Test , Humans , Hyperglycemia/blood , Insulin/blood , Tuberculosis, Pulmonary/bloodABSTRACT
Studied concentration of glycosylated hemoglobin in patiens with lung tuberculosis with disorders of tolerance to glucosis and glukemic disorders on an empty stomach and in patients, which had not such disorders. Medium of glycosylated hemoglobin concentration in patients with preclinical disorders glukemia takes middle position between of concentration HbA(1c) in healthy people and diabetes mellitus. This is indicative of stabilities of hyperglukemic episodes during previous 6-9 weeks. Got by us results persuasively about indicative of need of the goal-directed correction of preclinical disorders carbohydrate metabolism in patients with pulmonary tuberculosis.
Subject(s)
Blood Glucose/metabolism , Glycated Hemoglobin/metabolism , Tuberculosis, Pulmonary/blood , Case-Control Studies , Fasting , Female , Glucose Tolerance Test , Glycemic Index , Humans , Male , Tuberculosis, Pulmonary/physiopathologyABSTRACT
The technology of obtaining of specific immunoglobulin for serotherapy of neuroinfection caused by virus herpes simplex 1 type was developed. The patients presented with the following diseases: arachnoencephalitis, encephalopolyradiculoneuritis, encephalomyelitis, encephalitis, arachnoiditis, polyneuropathy, encephalomyelopolyradiculoneuritis, meningoencephalitis. The study showed good tolerance and safety of the medicine, no adverse effects registered during the study. The assessed median score of the efficacy was 2.8 from 3. The obtained results suggest using the liquid form preparation for intramuscular injection "Immunoglobulin for treatment of neuroinfection caused by virus herpes simplex type 1". The Close corporation "Biofarma" located in Kyiv produces this medicine.
